Text Size

Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Non-diabetic Patients With Critical Limb Ischemia.

This study is currently recruiting participants.
Verified January 2013 by Fundación Pública Andaluza Progreso y Salud
Sponsor:
Collaborator:
Iniciativa Andaluza en Terapias Avanzadas (IATA)
Information provided by (Responsible Party):
Fundación Pública Andaluza Progreso y Salud
ClinicalTrials.gov Identifier:
NCT01408381
First received: August 1, 2011
Last updated: January 10, 2013
Last verified: January 2013
History of Changes
  Purpose

Phase II Clinical Trial, a prospective, multicenter, open, randomized, parallel-group controlled with three levels of dose.

The hypothesis of the test we propose is that the mononuclear cells of bone marrow provide progenitor cells with regenerative capacity and besides secrete several angiogenic factors, and their implantation into ischemic tissues with both elements should contribute to angiogenesis and tissue regeneration with recovery of the circulation in the affected limb.


Condition Intervention Phase
Critical Limb Ischemia
 Other: Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multicenter Phase II, Randomized Open Clinical Trial on the Therapeutic Use of Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Non-diabetic Patients With Critical Chronic Ischemia of Lower Limbs.

Further study details as provided by Fundación Pública Andaluza Progreso y Salud:

Primary Outcome Measures:
  • Adverse events [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Ankle-brachial index [ Time Frame: 1 month, 3 months, 6 months ] [ Designated as safety issue: No ]
  • Transcutaneous oxygen pressure (TcO2) [ Time Frame: 1 month, 3 months, 6 months ] [ Designated as safety issue: No ]
  • Greater ulcer size [ Time Frame: 1 month, 3 months, 6 months ] [ Designated as safety issue: No ]
    Ulcer diameter will be recorded

  • Degree of Rutherford-Becker [ Time Frame: 1 month, 3 months, 6 months ] [ Designated as safety issue: No ]
  • Perimeter calf muscle [ Time Frame: 1 month, 3 months, 6 months ] [ Designated as safety issue: No ]
  • Presence of faster opacity in infrapopliteal vessels at 6 months compared with the basal situation of the patient. [ Time Frame: 1 month, 3 month, 6 month ] [ Designated as safety issue: No ]

Estimated Enrollment: 88
Study Start Date: January 2011
Estimated Study Completion Date: July 2013
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Control
No cell therapy
Experimental: Low dose
Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 1 x 108
 Other: Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells
Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x108, 5x108 and 1x109 low, intermediate and high dose in the arms respectively.
Experimental: Intermediate dose
Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 5 x 108
 Other: Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells
Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x108, 5x108 and 1x109 low, intermediate and high dose in the arms respectively.
Experimental: High dose
Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 1 x 109
 Other: Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells
Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x108, 5x108 and 1x109 low, intermediate and high dose in the arms respectively.

Detailed Description:

The study population will consist of a total of 88 non-diabetic patients with chronic critical ischemia in at least one of their lower limbs and without possibility of revascularization. In the experimental group will be included a total of 66 patients divided into three levels of dose, 22 patients in each level (increasing dose of mononuclear cells from autologous bone marrow) and other 22 patients in control group.

  • 22 patients in group 1 will not receive cell therapy, and they will only receive conventional treatment, acting as a control group.
  • 22 patients in group 2 will receive 1x108 autologous bone marrow mononuclear cells.
  • 22 patients in group 3 will receive 5x108 autologous bone marrow mononuclear cells.
  • 22 patients in group 4 will receive 1x109 autologous bone marrow mononuclear cells.

The cell therapy drug will be administered intra-arterially in all cases Patients will be evaluated by clinical, radiological and angiological methods (ankle / brachial pressure index, oximetry, digital arteriography).

Patients will receive concomitant drug treatment established by the good clinical practice, so undoubtedly it could be possible that some improvement occurs due to drug treatment.

It is estimated that the inclusion period is approximately 24 months, and the follow-up of each patient of six months. Therefore the total duration of the study will be about thirty months from the entry of the first patient to the end of the follow-up period of the last patient included.

The primary variable is the improvement in the vascularisation of the treated limb determined by clinical, angiographic and angiologist parameters.

Study objectives :

• Main objective: To evaluate the safety and feasibility of the autotransplantation of autologous bone marrow mononuclear cells administered intra-arterially in non-diabetic patients with critical chronic ischemia of the lower limbs without possibility of either revascularization or other therapeutic alternatives.

Secondary objectives:

  1. To compare the effect of three increasing dose of mononuclear cells from autologous bone marrow in the recovery of clinical, angiographic angiologist parameters in non-diabetic patients with critical chronic ischemia of lower limbs to a control group that will have been applied to a conventional treatment.
  2. To analyze complications from regenerative therapy itself, from the route of administration and / or study procedures.
  Eligibility

Ages Eligible for Study:   18 Years to 89 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients of both sexes aged ≥ 18 and ≤ 89 years.
  • Non-diabetic.
  • Infrapopliteal atherosclerotic vascular disease with severe to severe claudication or Rutherford-Becker grade I-3, II, III, in at least one lower limb. The chronic critical ischemia of the lower limb is defined as persistent / recurring pain requiring analgesia and / or non-healing ulcers present> 4 weeks, with no evidence of improvement with conventional therapies and / or walking test (stress test) between 1-6 minutes two exercise tests separated by at least 2 weeks and / or ankle-brachial index at rest <0.8.
  • Inability to endovascular or surgical revascularization as recommended by the TransAtlantic Inter-Society Consensus (TASC).
  • Failure of the revascularization surgical performed at least 30 days before, either persistently or entry in critical ischemia phase.
  • Life expectancy> 2 years.
  • Not expected major amputation in the limb to treat in the next 6 months after inclusion.

  • Normal laboratory parameters, defined by:

    1. Leukocytes ≥ 3000
    2. Neutrophils ≥ 1500
    3. Platelets ≥ 100,000
    4. Aspartate aminotransferase AST) / Alanine aminotransferase (ALT) ≤ 2.5 standard range institution.
    5. Creatinine ≤ 2.5 mg / dl
  • Patients should give their written informed consent to participate in the study.
  • Women of childbearing potential must have negative results on a pregnancy test following standard procedures for each hospital performed at the time of inclusion in the study and agree to use a medically approved method of contraception through the duration of the study.

Exclusion Criteria:

  • History of malignancy or hematologic disease (myeloproliferative disease, myelodysplastic syndrome or leukemia)
  • Patients with uncontrolled hypertension (defined as blood pressure> 180/110 on more than one occasion).
  • Severe heart failure (New York Heart Association IV).
  • Patients with malignant ventricular arrhythmias or unstable angina.
  • Diagnosis of deep vein thrombosis in the previous 3 months.
  • Active infection or gangrene wet day infusion of mononuclear bone marrow cells.
  • Corporal mass index (BMI)> 40 kg/m2.
  • Patients with a diagnosis of alcoholism at the time of inclusion.
  • Proliferative retinopathy.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01408381

Contacts
Contact: Ana Cardesa 0034 955019040 ana.cardesa@juntadeandalucia.es

Locations
Spain
University Hospital Reina Sofía Recruiting
Cordoba, Spain, 14004
Contact: Herrera, MD, PhD         inmaculada.herrera.sspa@juntadeandalucia.es    
Principal Investigator: Antonio Chacón, MD, PhD            
University Hospital Puerta del Mar Recruiting
Cádiz, Spain, 11009
Contact: Manuel Rodríguez         mropinero@ono.com    
Principal Investigator: Manuel Rodríguez, MD, PhD            
University Hospital San Cecilio Not yet recruiting
Granada, Spain, 18012
Contact: José Patricio Linares, MD, PhD         joseplinares@telefonica.net    
Principal Investigator: Jose Patricio Linares, MD, PhD            
University Hospital Virgen de las Nieves Recruiting
Granada, Spain, 18014
Contact: Vicente Garcia, MD, PhD         vgrospide@gmail.com    
Principal Investigator: Vicente Garcia, MD, PhD            
University General Hospital Morales Meseguer Not yet recruiting
Murcia, Spain, 30008
Contact: Diego de Alcalá, MD, PhD         diegoa@carm.es    
Principal Investigator: Diego de Alcalá, MD, PhD            
University Hopistal Carlos Haya Recruiting
Málaga, Spain, 29010
Contact: Fernando Calleja, MD, PhD         fkyeja@hotmail.com    
Principal Investigator: Fernando Calleja, MD, PhD            
University Hospital Nuestra Señora de Valme Not yet recruiting
Sevilla, Spain, 41014
Contact: Andrés García, MD, PhD         dr.andresgarcia@gmail.com    
Principal Investigator: Andrés García, MD, PhD            
Sponsors and Collaborators
Fundación Pública Andaluza Progreso y Salud
Iniciativa Andaluza en Terapias Avanzadas (IATA)
Investigators
Study Chair: Inmaculada Herrera, MD, PhD University Hospital Reina Sofía, Córdoba.
  More Information

Additional Information:
Andalusian Initiative for Advanced Therapies  This link exits the ClinicalTrials.gov site
Andalusian Molecular Biology and Regenerative Medicine Centre  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Fundación Pública Andaluza Progreso y Salud
ClinicalTrials.gov Identifier: NCT01408381     History of Changes
Other Study ID Numbers: CMMo/ICC/2009, 2009-013636-20
Study First Received: August 1, 2011
Last Updated: January 10, 2013
Health Authority: Spain: Spanish Agency of Medicines

Keywords provided by Fundación Pública Andaluza Progreso y Salud:
Critical Limb Ischemia
Cell Therapy
Bone marrow mononuclear cells

Additional relevant MeSH terms:
Ischemia
Pathologic Processes

ClinicalTrials.gov processed this record on May 16, 2013